Resona Asset Management Co. Ltd. Has $11.36 Million Stock Position in GE HealthCare Technologies Inc. $GEHC

Resona Asset Management Co. Ltd. trimmed its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 5.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 138,110 shares of the company’s stock after selling 8,499 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in GE HealthCare Technologies were worth $11,355,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in GEHC. Laurel Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter worth about $26,000. Optima Capital LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter worth about $27,000. Montag A & Associates Inc. boosted its holdings in shares of GE HealthCare Technologies by 105.4% in the fourth quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock worth $28,000 after buying an additional 175 shares during the period. Maseco LLP acquired a new position in shares of GE HealthCare Technologies in the fourth quarter worth about $29,000. Finally, Oakworth Capital Inc. boosted its holdings in shares of GE HealthCare Technologies by 1,876.2% in the third quarter. Oakworth Capital Inc. now owns 415 shares of the company’s stock worth $31,000 after buying an additional 394 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Rodney F. Hochman purchased 1,618 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were bought at an average price of $62.03 per share, with a total value of $100,364.54. Following the completion of the transaction, the director directly owned 1,618 shares in the company, valued at $100,364.54. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter J. Arduini purchased 4,169 shares of the company’s stock in a transaction dated Thursday, April 30th. The stock was purchased at an average cost of $59.92 per share, for a total transaction of $249,806.48. Following the transaction, the chief executive officer owned 259,424 shares of the company’s stock, valued at approximately $15,544,686.08. This trade represents a 1.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 11,847 shares of company stock valued at $719,555. 0.36% of the stock is owned by corporate insiders.

GE HealthCare Technologies Trading Up 4.4%

NASDAQ:GEHC opened at $64.26 on Thursday. GE HealthCare Technologies Inc. has a 12 month low of $58.75 and a 12 month high of $89.77. The firm has a market cap of $29.23 billion, a price-to-earnings ratio of 15.37, a P/E/G ratio of 1.39 and a beta of 0.74. The company has a quick ratio of 0.95, a current ratio of 1.22 and a debt-to-equity ratio of 0.95. The company’s 50 day moving average is $68.79 and its 200-day moving average is $76.40.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the prior year, the business earned $1.01 EPS. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on GEHC shares. Barclays decreased their target price on shares of GE HealthCare Technologies from $87.00 to $78.00 and set an “equal weight” rating for the company in a report on Thursday, April 30th. Rothschild & Co Redburn reduced their price target on shares of GE HealthCare Technologies from $110.00 to $98.00 in a research report on Thursday, April 30th. Citigroup reduced their price target on shares of GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research report on Thursday, April 30th. HSBC reduced their price target on shares of GE HealthCare Technologies from $100.00 to $90.00 in a research report on Thursday, April 30th. Finally, Argus reduced their price target on shares of GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, GE HealthCare Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $80.21.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.